Elevated TGF-β1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer

Domagała‐Kulawik, Joanna; Hoser, Grazyna; Safianowska, Aleksandra; Grubek-Jaworska, H; Chazan, Ryszarda

doi:10.1007/s00005-006-0016-0

Cited by 46 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also found that TGF-β in BALF was higher in NSCLC patients than in healthy controls. That is also in line with other studies in which the highest level of the protein has been reported in lung cancer of advanced stage (Domagała-Kulawik et al 2006). Distinct differences in BALF content of TGF-β protein between NSCLC and BBS patients, make this protein potentially useful in initial differential diagnosis.…”

Section: Discussionsupporting

confidence: 91%

Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer

Jakubowska

Naumnik

Niklińska

et al. 2015

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Lung cancer is associated with poor prognosis. The aim of this study was to evaluate the clinical usefulness of HMGB-1 (high-mobility group protein B1) and TGF-β (transforming growth factor beta) in patients with advanced non-small cell lung cancer (NSCLC). We studied 45 patients with NSCLC prior to chemotherapy, 23 patients with Besnier-Boeck-Schaumann (BBS) disease (sarcoidosis), and 15 healthy volunteers. HMGB-1 and TGF-β levels were measured in serum and BALF samples using ELISA method. A higher serum HMGB-1 and TGF-β levels were in NSCLC patients compared with the other groups. TGF-β concentration in BALF was significantly higher in NSCLC than in healthy controls (p=0.047) but lower than in BBS (p=0.016). Serum HMGB-1 in NSCLC correlated with age and gender while its level in BALF was associated with distant metastasis. A higher levels of HMGB-1 in the serum of NSCLC patients with progressive disease was linked with shorter overall survival and disease-free survival. We found a positive correlation between HMGB-1 and TGF-β in BALF of IIIB NSCLC group and overall survival (p=0.04; p=0.003). Our findings confirmed that the measurement of HMGB-1 and TGF-β levels in serum and BALF of patients with NSCLC prior to treatment may have clinical usefulness and predict poor prognosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer

Jakubowska

Naumnik

Niklińska

et al. 2015

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…TGFß1 regulates growth and proliferation of cells and may have a dual role in cancer (Tang et al 1999). This growth factor is involved in diVerent processes observed in malignancies, such as cellular proliferation, angiogenesis, immunological modulation, Wbroblast activation with remodeling of extracellular matrix and inXammation (Domagala-Kulawik et al 2006). TGFß1 inhibits the proliferation and induces the diVerentiation of normal bronchial epithelial cells (Elliott and Blobe 2005).…”

Section: Discussionmentioning

confidence: 99%

Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk

Teixeira

Araújo

Coelho

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Inflammation in COPD is characterized by prevalence of CD8 + lymphocytes, neutrophils, proinflammatory cytokines and a deficiency of regulatory lymphocytes [12]. Analysis involving the condition of immune system in patients with pulmonary carcinoma one must take into account history of cigarette smoking and potential diagnosis of COPD [15] .…”

Section: Analysis Of Immune System Cells In Lung Carcinomamentioning

confidence: 99%

Problems of Cancer Treatment. Part 2. Treatment Based on Modification of Anticancer Immunological Responses in Therapy

Kawiak

Hoser

Domagała‐Kulawik

2017

Advances in Cell Biology

Self Cite

View full text Add to dashboard Cite

Summary:Here we present the concept of making own patient's anti-cancer treatment more efficient and starting at testing the efficacy of immunological system. The respective tests are suggested, with special attention devoted to tumour-induced microenvironmental changes. The tumour should be considered to represent a complex tissue in which the cancer cells communicate directly and indirectly with the surrounding cellular immunological surrounding and develope traits that promote their own survival. The results of tests allow to propose a rational, individually profiled treatment of a patient, especially directed to elimination of blocks inhibiting the immunological system due to effects of cancer cells. The elimination can be implemented using commercially available antibodies, targeted at the cell surface receptors for inhibitors of T lymphocytes (CTLA-4 and PD-1). Outcome of the therapy is slow to appear and the results used to be selective. Some patients gain long term improvement and respective predictive markers are now tested. It is assumed that the future anti-cancer therapy will be individually targeted, based on individual tests and an assistance of own immunological system of the cancer patient.

show abstract

Elevated TGF-β1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer

Abstract: Our findings confirmed that TGF-beta takes part in the local response in the course of primary lung cancer.

Cited by 46 publications

References 29 publications

Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer

Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer

Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk

Problems of Cancer Treatment. Part 2. Treatment Based on Modification of Anticancer Immunological Responses in Therapy

Contact Info

Product

Resources

About